回复“慢性乙型肝炎患者停止使用核苷(t)类似物后肝炎爆发和肝脏失代偿的发生率”。

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2024-11-30 DOI:10.1016/j.jhep.2024.11.044

Edo J. Dongelmans, Harry L.A. Janssen

{"title":"回复“慢性乙型肝炎患者停止使用核苷(t)类似物后肝炎爆发和肝脏失代偿的发生率”。","authors":"Edo J. Dongelmans, Harry L.A. Janssen","doi":"10.1016/j.jhep.2024.11.044","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Clinical trial number</h2>not applicable.</section></section><section><section><h2>Author contributions</h2>Edo Dongelmans, MD (Conceptualization: Equal; Writing – original draft: Lead). Harry L.A. Janssen, MD, PhD (Conceptualization: Equal; Supervision: Lead; Writing – review & editing: Equal).</section></section><section><section><h2>Data availability statement</h2>not applicable.</section></section><section><section><h2>Financial support</h2>No funding was received for this article.</section></section><section><section><h2>Declaration of Competing Interest:</h2>Edo Dongelmans has no conflicts of interests. Harry Janssen received grants from: Gilead Sciences, GlaxoSmithKline, Janssen, Roche, Vir Biotechnology Inc. and is consultant for: Aligos, Gilead Sciences, GlaxoSmithKline, Janssen, Roche, Vir Biotechnology Inc., Precision Biosciences, Griffols.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"27 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reply to “The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide analogue cessation in chronic hepatitis B patients.”\",\"authors\":\"Edo J. Dongelmans, Harry L.A. Janssen\",\"doi\":\"10.1016/j.jhep.2024.11.044\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h2>Section snippets</h2><section><section><h2>Clinical trial number</h2>not applicable.</section></section><section><section><h2>Author contributions</h2>Edo Dongelmans, MD (Conceptualization: Equal; Writing – original draft: Lead). Harry L.A. Janssen, MD, PhD (Conceptualization: Equal; Supervision: Lead; Writing – review & editing: Equal).</section></section><section><section><h2>Data availability statement</h2>not applicable.</section></section><section><section><h2>Financial support</h2>No funding was received for this article.</section></section><section><section><h2>Declaration of Competing Interest:</h2>Edo Dongelmans has no conflicts of interests. Harry Janssen received grants from: Gilead Sciences, GlaxoSmithKline, Janssen, Roche, Vir Biotechnology Inc. and is consultant for: Aligos, Gilead Sciences, GlaxoSmithKline, Janssen, Roche, Vir Biotechnology Inc., Precision Biosciences, Griffols.</section></section>\",\"PeriodicalId\":15888,\"journal\":{\"name\":\"Journal of Hepatology\",\"volume\":\"27 1\",\"pages\":\"\"},\"PeriodicalIF\":26.8000,\"publicationDate\":\"2024-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jhep.2024.11.044\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.11.044","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

临床试验编号不适用。sedo Dongelmans， MD(概念化：Equal；写作-原稿：Lead)。Harry L.A. Janssen， MD, PhD(概念：平等；监督:铅;写作-回顾&；编辑:平等)。数据可用性声明不适用。财政支持本文未收到任何资助。▽竞争利益声明=江户东门没有利益冲突。Harry Janssen从：Gilead Sciences， GlaxoSmithKline, Janssen, Roche, Vir Biotechnology Inc.获得资助，并担任：Aligos， Gilead Sciences, GlaxoSmithKline, Janssen, Roche, Vir Biotechnology Inc., Precision Biosciences， Griffols的顾问。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Reply to “The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide analogue cessation in chronic hepatitis B patients.”

Section snippets

Clinical trial number

not applicable.

Author contributions

Edo Dongelmans, MD (Conceptualization: Equal; Writing – original draft: Lead). Harry L.A. Janssen, MD, PhD (Conceptualization: Equal; Supervision: Lead; Writing – review & editing: Equal).

Data availability statement

not applicable.

Financial support

No funding was received for this article.

Declaration of Competing Interest:

Edo Dongelmans has no conflicts of interests. Harry Janssen received grants from: Gilead Sciences, GlaxoSmithKline, Janssen, Roche, Vir Biotechnology Inc. and is consultant for: Aligos, Gilead Sciences, GlaxoSmithKline, Janssen, Roche, Vir Biotechnology Inc., Precision Biosciences, Griffols.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.